HK1049961B - Method of treating cancer with anti-neurotrophin agents - Google Patents

Method of treating cancer with anti-neurotrophin agents Download PDF

Info

Publication number
HK1049961B
HK1049961B HK03102054.6A HK03102054A HK1049961B HK 1049961 B HK1049961 B HK 1049961B HK 03102054 A HK03102054 A HK 03102054A HK 1049961 B HK1049961 B HK 1049961B
Authority
HK
Hong Kong
Prior art keywords
neurotrophin
day
antibodies
antibody
tumor
Prior art date
Application number
HK03102054.6A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1049961A1 (en
Inventor
Karen J. Buchkovich
Craig A. Dionne
Sheila J. Miknyoczki
Bruce A. Ruggeri
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of HK1049961A1 publication Critical patent/HK1049961A1/en
Publication of HK1049961B publication Critical patent/HK1049961B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK03102054.6A 2000-02-29 2001-02-28 Method of treating cancer with anti-neurotrophin agents HK1049961B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18594300P 2000-02-29 2000-02-29
US793850 2001-02-27
US09/793,850 US6548062B2 (en) 2000-02-29 2001-02-27 Method of treating cancer with anti-neurotrophin agents
PCT/US2001/006266 WO2001064247A2 (en) 2000-02-29 2001-02-28 Method of treating cancer with anti-neurotrophin agents

Publications (2)

Publication Number Publication Date
HK1049961A1 HK1049961A1 (en) 2003-06-06
HK1049961B true HK1049961B (en) 2007-09-14

Family

ID=26881613

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03102054.6A HK1049961B (en) 2000-02-29 2001-02-28 Method of treating cancer with anti-neurotrophin agents

Country Status (13)

Country Link
US (1) US6548062B2 (enExample)
EP (1) EP1261372B1 (enExample)
JP (1) JP2003525253A (enExample)
CN (1) CN1227033C (enExample)
AT (1) ATE361100T1 (enExample)
AU (2) AU2001239913B2 (enExample)
CA (1) CA2401604C (enExample)
DE (1) DE60128208T2 (enExample)
ES (1) ES2286110T3 (enExample)
HK (1) HK1049961B (enExample)
MX (1) MXPA02008465A (enExample)
NZ (1) NZ521165A (enExample)
WO (1) WO2001064247A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
JP3773733B2 (ja) * 2000-01-13 2006-05-10 松下電器産業株式会社 陰極線管
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
CN1684708A (zh) * 2001-05-30 2005-10-19 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US20060147450A1 (en) * 2002-10-04 2006-07-06 Shelton David L Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
JP4584713B2 (ja) * 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
FR2846426B1 (fr) * 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CN101014364B (zh) * 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
PL379983A1 (pl) * 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
US20050043215A1 (en) * 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
EA013614B1 (ru) * 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
ES2616337T3 (es) * 2003-12-12 2017-06-12 Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP3372614B1 (en) * 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
NZ556157A (en) 2005-01-24 2009-09-25 Elan Pharma Int Ltd Specific binding members for NGF
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
RS53661B1 (sr) 2007-08-10 2015-04-30 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
US20110229485A1 (en) * 2008-05-21 2011-09-22 Centre National De La Recherche Scientfique (Cnrs) Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
JP2012515158A (ja) 2009-01-12 2012-07-05 武田薬品工業株式会社 癌の予防・治療剤
EA201190115A1 (ru) 2009-01-24 2012-02-28 ФИТОФАРМ ПиЭлСи Лечение расстройств, опосредованных нейротрофическим фактором
US8435523B2 (en) * 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
CA2808577C (en) 2010-08-19 2018-09-25 Abbott Laboratories Anti-ngf antibodies and their use
JP6105838B2 (ja) * 2010-08-24 2017-03-29 国立大学法人 岡山大学 疼痛の治療剤
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
AU2013271564A1 (en) 2012-06-06 2014-12-04 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
EP2859019B1 (en) 2012-06-08 2018-02-21 Glenmark Pharmaceuticals S.A. Humanized anti-trka antibodies with amino acid substitutions
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CA3093772C (en) 2018-03-12 2024-04-16 Zoetis Services Llc Anti-ngf antibodies and methods thereof
MX2024007088A (es) 2021-12-16 2024-08-22 Intervet Int Bv Anticuerpos caninizados contra el ngf humano.
EP4514998A1 (en) 2022-04-27 2025-03-05 Regeneron Pharmaceuticals, Inc. Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score
US20240310383A1 (en) 2023-03-17 2024-09-19 Regeneron Pharmaceuticals, Inc. Proteomic Risk Score For Osteoarthritis (OA)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1073264A (zh) 1991-11-12 1993-06-16 里珍纳龙药品有限公司 基于组织的特定的nt-3表达与受体结合的治疗和诊断方法
AU5102493A (en) 1992-09-11 1994-04-12 Cephalon, Inc. A method for the detection and treatment of prostate disease
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
EP0753013A1 (en) * 1994-03-29 1997-01-15 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Neurotrophin-6: a new member of the neurotrophin family

Also Published As

Publication number Publication date
AU2001239913B2 (en) 2005-12-08
HK1049961A1 (en) 2003-06-06
ES2286110T3 (es) 2007-12-01
CA2401604A1 (en) 2001-09-07
MXPA02008465A (es) 2003-03-10
CA2401604C (en) 2011-05-24
WO2001064247A3 (en) 2002-02-14
EP1261372A2 (en) 2002-12-04
JP2003525253A (ja) 2003-08-26
NZ521165A (en) 2004-08-27
US20010046959A1 (en) 2001-11-29
EP1261372B1 (en) 2007-05-02
CN1227033C (zh) 2005-11-16
ATE361100T1 (de) 2007-05-15
DE60128208D1 (de) 2007-06-14
CN1420785A (zh) 2003-05-28
DE60128208T2 (de) 2008-01-10
US6548062B2 (en) 2003-04-15
AU3991301A (en) 2001-09-12
WO2001064247A2 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
EP1261372B1 (en) Method of treating cancer with anti-neurotrophin agents
AU2001239913A1 (en) Method of treating cancer with anti-neurotrophin agents
KR101220635B1 (ko) 신규한 항-ｉｇｆ-ｉｒ 항체 및 그의 용도
KR101699432B1 (ko) 섬유아세포성장인자수용체 ２에 대한 모노클로날 항체
AU687346B2 (en) A combination of anti-erbB-2 monoclonal antibodies and method of using
US20120230991A1 (en) Methods and compounds for enhancing anti-cancer therapy
CN110882385B (zh) 抗pd-1抗体在治疗肿瘤中的用途
EA018717B1 (ru) Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение
JP2009155335A (ja) 抗癌療法のためのマクロファージマイグレーション阻害因子アンタゴニストの使用
TW201002346A (en) Combination of HGF inhibitor and EGF inhibitor to treat cancer
KR20040010613A (ko) 항암 항체
TW200948380A (en) Combination of HGF inhibitor and PTEN agonist to treat cancer
EP0569141A2 (en) Methods of inhibiting the growth of multidrug resistant tumors with an antibody
EP4365201A1 (en) Anti-gfral antibody and application thereof
CN121079314A (zh) 用于组合疗法的方法和组合物
EP2824113B1 (en) Biomarker for selecting a subject for application of an anti-c-met antibody
WO2022075482A1 (ja) がん治療用医薬
CN113710321A (zh) 用于治疗癌症的方法和组合物
CA2459622C (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
KR20240143955A (ko) Api5 에피토프 및 이에 특이적으로 결합하는 항체
HK40085220A (en) Antibody drug conjugate formulation and use thereof
Li et al. a potent and selective cell permeable inhibitor Menu
KR20050021001A (ko) 인간 인슐린-유사 성장인자-i 수용체 항체
EP1757305A2 (en) Individualized anti-cancer antibodies

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170228